Earnings Summary for Wave Life Sciences Ltd for Q2 2024
Intellectia.AI1970-01-01
Earnings Summary for Wave Life Sciences Ltd. for Q2 2024
Wave Life Sciences Ltd. Reports Second Quarter Financial Results
Wave Life Sciences Ltd. reported its financial results for the quarter ended June 30, 2024.
Key Financial Metrics
| Metric | Q2 2024 | QoQ Comparison | YoY Comparison |
|---|---|---|---|
| Total Revenue | $19.7 million | -10.86% (Decrease) | -10.86% (Decrease) |
| Net Loss | $32.9 million | -12.49% (Increase) | -56.07% (Increase) |
Interpretation: The total revenue for Q2 2024 was $19.7 million, reflecting a slight decrease both quarter-over-quarter and year-over-year. The company had a net loss of $32.9 million for the second quarter.
Revenue Performance by Segment
| Segment | Revenue |
|---|---|
| GSK Collaboration | $19.1 million |
| Takeda Collaboration | $0.6 million |
Interpretation: The GSK Collaboration remained the primary revenue driver, contributing $19.1 million, while the Takeda Collaboration contributed $0.6 million during Q2 2024.
Stock Price Movement After Release
| After Event % Change |
|---|
| -5.94% |
Summary: Following the earnings release, Wave Life Sciences Ltd.'s stock price decreased by approximately 5.94%.
Note: This summary contains only the information provided in the earnings release and the attached report. Any sections not mentioned lacked sufficient data for completion.
Tesla's Robotaxi Launch Sparks New Market Momentum: What Investors Need to Know
Great News for Lucid Investors: Is Now the Time to Buy Lucid Stock?
Exploring IonQ Stock: Is This Quantum Computing Pioneer a Smart Investment?
Share